Spero Therapeutics

Spero Therapeutics

Yahoo Finance • 2 days ago

Spero outlines cash runway into the second half of 2029 following $105M royalty financing

Earnings Call Insights: Spero Therapeutics (SPRO) Q2 2026 MANAGEMENT VIEW * "In the last 90 days, we had 4 major milestones. The FDA approved Utebzi... We in-licensed SP001 and repositioned the company's pipeline to focus on immune-med... Full story

Yahoo Finance • 19 days ago

Spero Therapeutics Names Debra Jeske Zack As Chief Medical Officer

(RTTNews) - Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company, on Monday said it has appointed Debra Jeske Zack as Chief Medical Officer. The company said the appointment will strengthen its clinical leadership... Full story

Yahoo Finance • last month

Spero inks $105M financing deal with KKR affiliate

* Spero Therapeutics (SPRO [https://seekingalpha.com/symbol/SPRO]) said that [https://seekingalpha.com/pr/20581282-spero-therapeutics-announces-105-million-non-recourse-non-dilutive-financing-backed-by-a] it secured $105M in non-recourse... Full story

Yahoo Finance • last month

Avacta Appoints Patrick Vink As Deputy Chairman & Senior Independent Director To Its Board

(RTTNews) - Avacta Group Plc (AVCT.L), a biopharmaceutical company developing pre|CISION oncology technology, announced the appointment of Patrick Vink as Non-Executive Deputy Chairman and Senior Independent Director to its Board of Direct... Full story

Yahoo Finance • 2 months ago

Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer

WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corpor... Full story

Yahoo Finance • 2 months ago

Weekly Buzz: SPRO, ABBV Get FDA Nod, NMRA Halts KOASTAL; ENGN Cuts Jobs; BIIB Acquires RayThera

(RTTNews) - This week, the biotech sector saw FDA approvals, alongside study halts, layoffs, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical readouts spanning therapeutic areas inclu... Full story

Yahoo Finance • 2 months ago

Spero: FDA Approves Utebzi, The First Oral Carbapenem For Complicated UTIs In Adults; Stock Up

(RTTNews) - GSK plc (GSK) and Spero Therapeutics (SPRO) announced that the U.S. FDA has approved Utebzi (tebipenem pivoxil) as the first and only oral carbapenem antibiotic for adults with complicated urinary tract infections, including py... Full story

Yahoo Finance • 5 months ago

Spero Therapeutics Non-GAAP EPS of $0.53, revenue of $41.3M

* Spero Therapeutics press release [https://seekingalpha.com/pr/20453311-spero-therapeutics-announces-fourth-quarter-and-full-year-2025-operating-results-and-provides] (SPRO [https://seekingalpha.com/symbol/SPRO]): Q4 Non-GAAP EPS of $0.... Full story

Yahoo Finance • 5 months ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026

CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unme... Full story

Yahoo Finance • 6 months ago

Airgain And 2 Other Promising Penny Stocks

As February begins, the U.S. stock market has shown a robust start with major indexes like the Dow Jones Industrial Average and S&P 500 ending sharply higher. For those looking to invest in smaller or newer companies, penny stocks—despite... Full story

Yahoo Finance • 9 months ago

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MD... Full story

Yahoo Finance • 10 months ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with regulatory authorities to support regu... Full story

Yahoo Finance • last year

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

PIVOT-PO Phase 3 trial evaluating tebipenem Hbr in complicated urinary tract infection (cUTI) patients stopped early for efficacy following review by independent data monitoring committee (IDMC)Spero, along with its development partner, GS... Full story

Yahoo Finance • last year

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

CAMBRIDGE, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MD... Full story

Yahoo Finance • last year

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

Spero Therapeutics, Inc. (NASDAQ:SPRO) saw its stock surge by 240% on May 28 following the company's announcement of the successful completion of the pivotal Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral antibiotic inte... Full story

Yahoo Finance • last year

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

Pre-specified interim analysis of the ongoing Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI), including acute pyelonephritis (AP), on track to be completed in Q2 2025Existing cash, together w... Full story

Yahoo Finance • last year

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 s... Full story

Yahoo Finance • last year

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and mul... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Spero Therapeutics Inc. (NASDAQ: SPRO)

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Spero Therapeutics Inc. (NASDAQ: SPRO) concerning possible breaches of fiduciary duty. To obtain additional information, go... Full story

Yahoo Finance • 3 years ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need are... Full story